 DARTMOUTH, Nova Scotia--BUSINESS WIRE--- IMV DeliveryPlatform--IMV Inc. NASDAQ: IMV; TSX: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced the final topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S MVP-S, formerly known as DPX-Survivac in subjects with advanced recurrent ovarian cancer. The overall results obtained from the DeCidE1 trial are very promising, said Dr. Oliver Dorigo, Prin 